Aptamer Group updates on progress in Unilever partnership

Unilever plc

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has provided an update on the partnership with Unilever to deliver Optimer binders for cosmetic applications.

In 2022, Aptamer initiated a partnership with Unilever for the development of Optimer binders with the aim of treating malodour in personal care products. Following successful Optimer development, the binders have been rigorously tested at both Aptamer Group and Unilever showing highly positive and reproducible results, indicating their potential for use in downstream products.

Based on these results, a patent was submitted on 28 March 2024, to protect the developed Optimer binders and give Aptamer Group precedence for the protection of the intellectual property.

Work to test the Optimer binders is ongoing in Unilever’s labs. Unilever plans to conduct on-person functionality studies in the second half of 2024.

The global deodorant market alone was valued at $25.6 billion in 2023, with Unilever being the market leader as the largest antiperspirant and deodorant manufacturer in the world.

It is anticipated that this project will be completed over the next two years, and if successful, could result in Aptamer licensing the Optimer binders to Unilever.

Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: “I’m pleased to provide this update on our work with Unilever. The early success we have seen to date in evaluating our Optimers that aim to treat malodour has been promising. We are excited to support our partners at Unilever in advancing these binders to the next stage of development with on-person functionality studies. Fast-moving consumer goods (FMCG) like personal care products can progress to market more rapidly than diagnostics or therapeutic products. Optimers offer advantages such as stability, shelf life and consistent manufacturability making them ideal molecules for FMCG / cosmetic applications.  If the Optimer binders continue to progress through the testing and manufacturing stages in Unilever’s hands, then we anticipate the completion of this project within two years.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer signs therapeutic development deal with Invizius

    Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform, currently in Phase 2 trials, by providing safer and more precise therapies, including potential treatments for IgA nephropathy.

    Aptamer advances enzyme modulation projects and expands pharma collaboration

    Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors.

    Aptamer secures contract Eetension with top 5 pharma partner

    Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities.

    Aptamer Group to host technical development update webinar

    Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.

    Aptamer Group reports 41% revenue growth and new licensing deals

    Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise.

    Aptamer Group extends Unilever collaboration for deodorant Optimers

    Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.

      Search

      Search